Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Ambroxol is a mucolytic medicine used in several countries to treat airway disorders associated with abnormal mucus secretion and impaired mucus clearance. Oral products include liquids, tablets, capsules, and lozenges, depending on the market. Ambroxol is not an FDA-approved treatment for Gaucher disease, despite receiving U.S. orphan-drug designations for research in that condition.
read more about ambroxol ...Ambroxol acts as a mucolytic and expectorant. It changes airway secretions so mucus becomes thinner and easier to move out of the respiratory tract. Regulatory product information outside the United States describes its use for lung and airway diseases with abnormal mucus secretion or impaired clearance. Product strength and dosing differ across countries and formulations.
Ambroxol-containing medicines are authorized in numerous European countries through national procedures and are mainly used as expectorants for respiratory conditions with thick mucus. Approved uses are not identical across countries. Some ambroxol lozenges are used for sore throat, while selected injectable formulations outside the United States have separate respiratory indications.
Dosing depends on the specific product, concentration, age group, and national label. One authorized 6 mg/mL oral liquid uses age-based dosing and is contraindicated in children younger than 2. Adults and children older than 12 receive higher measured doses than younger children. Patients should follow the instructions for the exact local product rather than applying a dose from another formulation.
Ambroxol has been linked to allergic reactions and rare severe skin reactions, including erythema multiforme and Stevens-Johnson syndrome. European regulators require these risks in product information. Progressive skin rash, blisters, mouth sores, facial swelling, or breathing difficulty call for immediate discontinuation and medical assessment. Other adverse effects vary by formulation and local product label.
Yes. Ambroxol is used as a mucolytic and expectorant in several countries to thin mucus and aid airway clearance.
No. FDA orphan-drug records list ambroxol for Gaucher disease research, but those designations do not equal approval for that indication.
No. Formulations, approved uses, strengths, age limits, and dosing instructions differ across national product labels.
Yes. European regulators list rare severe cutaneous reactions and instruct patients to stop treatment if progressive rash symptoms appear.
Ambrobene Extra Strength 6 mg/ml Oral Solution Summary of Product Characteristics. https://assets.hpra.ie/products/Human/21191/LicenseSPC_PA0749-158-002_03082016152042.pdf. Date Accessed September 11, 2026.
Ambroxol and Bromhexine-Containing Medicines - Referral. https://www.ema.europa.eu/en/medicines/human/referrals/ambroxol-bromhexine-containing-medicines. Date Accessed September 11, 2026.
Ambroxol and Bromhexine Expectorants: Safety Information to Be Updated. https://www.ema.europa.eu/en/news/ambroxol-bromhexine-expectorants-safety-information-be-updated. Date Accessed September 11, 2026.
Search Orphan Drug Designations and Approvals - Ambroxol, Gaucher Disease, Designated June 29, 2011. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=262308. Date Accessed September 11, 2026.
Search Orphan Drug Designations and Approvals - Ambroxol, Gaucher Disease, Designated April 16, 2025. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1071325. Date Accessed September 11, 2026.